Lisheng Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 78.326 million yuan, down 77.16% from the same period last year. Total operating revenue was 642 million yuan, down 12.29% year-on-year. Net cash flow from operating activities was negative 44.1915 million yuan, down 163.28% year-on-year. The company's latest gross margin was 55.69%, up 0.38 percentage points from the previous quarter, marking two consecutive quarters of increase. Latest return on equity was 1.75%, down 5.11 percentage points from the same period last year. Diluted earnings per share were 0.25 yuan, down 77.48% year-on-year.
Tianjin Lisheng Pharmaceutical Co LtdNet profit fell 77.16% year-on-year, revenue down 12.29%, and operating cash flow turned negative.
